Petrucci MT - Search Results

1

Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia.

Ricciardi MR, Petrucci MT, Gregorj C, Ariola C, Lemoli RM, Fogli M, Mauro FR, Cerretti R, Foà R, Mandelli F, Tafuri A. Ricciardi MR, et al. Among authors: petrucci mt. Br J Haematol. 2001 May;113(2):391-9. doi: 10.1046/j.1365-2141.2001.02708.x. Br J Haematol. 2001. PMID: 11380404 Free article.

2

[Interferon: a new weapon in the therapeutic strategy of multiple myeloma].

Avvisati G, Petrucci MT, Mandelli F. Avvisati G, et al. Among authors: petrucci mt. Haematologica. 1990 Jul-Aug;75 Suppl 4:68-71. Haematologica. 1990. PMID: 1705913 Review. Italian. No abstract available.

3

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribalto M, Vegna ML, et al. Mandelli F, et al. Among authors: petrucci mt. N Engl J Med. 1990 May 17;322(20):1430-4. doi: 10.1056/NEJM199005173222005. N Engl J Med. 1990. PMID: 2184356 Free article. Clinical Trial.

4

High serum IL-2 levels are predictive of prolonged survival in multiple myeloma.

Cimino G, Avvisati G, Amadori S, Cava MC, Giannarelli D, Di Nucci GD, Magliocca V, Petrucci MT, Poti G, Sgadari C, et al. Cimino G, et al. Among authors: petrucci mt. Br J Haematol. 1990 Jul;75(3):373-7. doi: 10.1111/j.1365-2141.1990.tb04351.x. Br J Haematol. 1990. PMID: 2386771

5

Interferon: a new strategy in the treatment of multiple myeloma.

Mandelli F, Avvisati G, Petrucci MT. Mandelli F, et al. Among authors: petrucci mt. Eur J Haematol Suppl. 1989;51:129-34. doi: 10.1111/j.1600-0609.1989.tb01505.x. Eur J Haematol Suppl. 1989. PMID: 2483380 Review. No abstract available.

6

Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients.

Petrucci MT, Avvisati G, Tribalto M, Giovangrossi P, Mandelli F. Petrucci MT, et al. J Intern Med. 1989 Dec;226(6):443-7. doi: 10.1111/j.1365-2796.1989.tb01422.x. J Intern Med. 1989. PMID: 2518735

7

Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.

Petrucci MT, Avvisati G, Tribalto M, Cantonetti M, Giovangrossi P, Mandelli F. Petrucci MT, et al. Eur J Haematol. 1989 Mar;42(3):233-7. doi: 10.1111/j.1600-0609.1989.tb00104.x. Eur J Haematol. 1989. PMID: 2924885

8

Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol.

Mandelli F, Tribalto M, Avvisati G, Cantonetti M, Petrucci MT, Boccadoro M, Pileri A, Marmont F, Resegotti L, Lauta V, et al. Mandelli F, et al. Among authors: petrucci mt. Cancer Treat Rev. 1988 Jan;15 Suppl A:43-8. doi: 10.1016/0305-7372(88)90073-4. Cancer Treat Rev. 1988. PMID: 3277709 Clinical Trial. No abstract available.

9

Interleukin-3 priming in acute myeloid leukaemia patients.

Tafuri A, de Felice L, Goodacre A, Fenu S, Petrucci MT, Valentini T, Alimena G, Petti MC, Meloni G, Mandelli F, et al. Tafuri A, et al. Among authors: petrucci mt. Br J Haematol. 1995 Sep;91(1):234-44. doi: 10.1111/j.1365-2141.1995.tb05276.x. Br J Haematol. 1995. PMID: 7577641

10

Effects of mast cell growth factor on Ara-C mediated acute myeloid leukemia cell killing.

Tafuri A, De Felice L, Mascolo MG, Valentini T, Petrucci MT, Petti MC. Tafuri A, et al. Among authors: petrucci mt. Stem Cells. 1993 Jul;11 Suppl 2:88-92. doi: 10.1002/stem.5530110815. Stem Cells. 1993. PMID: 7691332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

256 results

Search Page